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Background: Aurora A kinase, a centrosomal serine/threonine kinase which plays an essential role in chromosome
segregation during cell division, is commonly amplified and/or over expressed in human malignancies. Aurora A is
suggested to be one of the proliferation parameters which is an independent prognostic factor for early invasive
breast cancer patients; however the individual clinical or prognostic relevance of this gene has been a matter
of debate.
Methods: A comprehensive analysis of Aurora A at the levels of gene expression, gene copy number and protein
expression was performed for 278 primary invasive breast cancer patients; and the correlation with clinical
outcomes were investigated.
Results: Aurora A gene expression level not only correlated with gene amplification, but was also significantly
associated with several clinicopathological parameters and patient prognosis. Patients with higher nuclear grade,
negative progesterone receptor status and higher Ki67 expressed higher levels of Aurora A mRNA, which was
associated not only with poor relapse-free survival (RFS) but was also found to be a significant multivariate
parameter for RFS. Aurora A protein expression was also significantly associated with clinicopathological
characteristics; lymph node status, nuclear grade, estrogen receptor status and Ki67, but not with prognosis.
By contrast, Aurora A gene amplification correlated with tumor size, nuclear grade and Ki67, and had no
prognostic value.
Conclusion: Our data indicate that Aurora A gene expression is an effective tool, which defines both tumor
proliferation potency and patient prognosis.
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Aurora kinases, centrosomal serine/threonine kinases,
are members of the kinase family involved in cell di-
vision, and play an essential role in chromosome segre-
gation during cell division through their establishment
of bipolar spindles. There are three types of Aurora ki-
nases in mammals, Aurora A, B and C. They differ in
length and in the sequence of the amino terminal* Correspondence: ys-yama@triton.ocn.ne.jp
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distribution, and reproduction in any mediumdomain and have different intracellular locations reflec-
ting their different functions in the cell cycle [1]. The
human Aurora A gene is located on chromosome seg-
ment 20q13, a segment which is commonly amplified
and/or overexpressed in several human epithelial ma-
lignancies, including colon, bladder, ovary, pancreas, and
breast [2-6]. Aurora A amplification and/or overexpres-
sion has been associated with centrosome anomalies and
chromosomal instability as well as abrogation of DNA
damage-induced apoptotic response and spindle assem-
bly checkpoint override in tumor cells, and as a result
Aurora A was defined as an oncogene [7,8]. Further-
more, Aurora A overexpression has been found to cor-
relate with phosphorylation of tumor suppressors suchtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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suggesting a role in the unregulated proliferation and re-
sistance to DNA damage-induced apoptosis in breast
cancer [10].
Nowadays, intrinsic molecular subtypes identified by
global microarray-based gene expression analysis can be
used to categorize breast cancer, which displays great
diversity and molecular heterogeneity [11]. Moreover,
more convenient tools for the analysis of gene ex-
pression together with clinical outcome data, such as
Oncotype Dx [12], Mammaprint [13], and PAM50 [14],
have been developed and used in prognostic assessments
and prediction of therapeutic efficacy for high risk of
recurrence in early breast cancer patients. These gene
analysis tools include the majority of proliferation or
cell-cycle-related genes, including Aurora A, which acts
as a powerful prognostic factor in line with estrogen re-
ceptor (ER) or human epidermal growth factor receptor
type2 (HER2) status. In view of the clinical significance
of Aurora A in breast cancer, overexpression has been
correlated with high nuclear grade in only a tiny number
of studies but these studies indicate that gene amplifica-
tion and/or overexpression of Aurora A are linked to
tumorigenesis [1,2,7]. In particular, a recent study sug-
gested that Aurora A protein expression outperforms
other proliferation makers, such as Ki67 protein, in ER
positive breast cancer [15]. Whereas several studies have
assessed the expression levels of Aurora A itself, explor-
ing its clinical significance, there have been none which
have compared mRNA expression, copy number aberra-
tion and protein expression, and the correlation of each.
In the present study, we examined the expression
levels of Aurora A (AURKA) mRNA, amplification of
gene copy number and protein expression in a cohort of
patients with primary invasive breast cancer. The rela-
tionship between Aurora A status and clinicopathologi-
cal characteristics and prognosis was evaluated.
Methods
Patients and breast cancer tissues
Breast tumor specimens from 278 consecutive female
patients with primary invasive breast carcinoma, who
were treated at Kumamoto University Hospital between
2001 and 2008, were included in this study. No exclu-
sion criteria were applied. The study was reported ac-
cording to the Reporting Recommendations for Tumor
Marker Prognostic Studies (REMARK) criteria [16]. All
patients had undergone pretherapeutic biopsy or surgical
treatment. Samples were snap frozen in liquid nitrogen
and stored at −80°C until used for simultaneous total
RNA and genomic DNA extraction. Adjuvant treatment
and neoadjuvant treatment were decided by risk evalua-
tion according to tumor biology (ER, PgR, and HER2 ex-
cept Ki-67 status) and clinical staging, including sentinellymph node biopsy, in accordance with the recommen-
dations of the St. Gallen international expert consensus
on the primary therapy of early breast cancer [11,17-19].
In detail, neoadjuvant treatments were administered to
62 patients; 46 of whom received chemotherapy and
16, hormonal therapy. The breast conserving rate was
68.2%, and most of these were treated with radiotherapy.
Axillary lymph node dissection was carried out in 45.2%
of cases; others were omitted dissection due to negative
lymph node status by sentinel node exploration. A total
of 208 patients were treated with hormone therapy; aro-
matase inhibitors (AI): 124, tamoxifen (TAM): 20, TAM-
AI: 20, ovarian function suppression plus TAM: 44. One
hundred six patients were administered chemotherapy;
anthracycline-containing regimens (ACR) followed by
taxanes: 68, ACR only: 20, taxanes only: 9, others: 9, and
19 patients were treated with trastuzumab. The ethics
committee of Kumamoto University Graduate School of
Medical Sciences approved the study protocol. Informed
consent was obtained from all patients. Patients were
followed postoperatively every 3 months. The median
follow-up period was 53 months (range 5-121 months).
RNA extraction and real-time quantitative reverse
transcription-polymerase chain reaction
Total RNA was isolated from the 278 snap-frozen speci-
mens using an RNeasy Mini Kit (Qiagen, Germantown,
MD, USA) according to the manufacturer’s instructions.
RNA was quantified by measuring the A260/A280 ab-
sorbance ratios (Nano-Drop Technologies, Wilmington,
DE). RNA was qualitatively assessed using the Agilent
2100 Bioanalyzer (Expert Software version B.02.03)
with RNA Nano LabChip Kits (Agilent Technologies,
Stockport, UK). Total RNA (0.5 μg) was reverse trans-
cribed to cDNA using PrimeScript® RT Master Mix
(Takara Bio Inc., Otsu, Japan), according to the manufac-
turer's protocol. Reverse transcription real-time quantita-
tive polymerase chain reaction (RT-qPCR) was performed
with 15 ng of the cDNA and 0.2 μmol/L of each assay in
the ABI Prism 7500 (Applied Biosystems, Carlsbad, CA)
by the comparative method with TaqMan chemistry. PCR
primers were as follows: TaqMan gene expression assay
AURKA; Hs01582073_m1, ACTB; Hs01060665_g1,
PUM1; Hs00982775_m1, TAF-10; Hs00359540_g1 (Ap-
plied Biosystems). Each reaction was performed under
the following conditions: initialization for 20 s at 95°C,
and then 40-cycles of amplification, comprising 3 s at
95°C for denaturation and 30 s at 60°C for annealing
and elongation. The maximum cycle threshold (Ct)
value was set at 40. Relative expression values of each gene
per sample (the raw Ct data) were calculated by SDS 2.2
software (Applied Biosystems), with expression defined as
the point at which the fluorescence rises above the
background fluorescence. Data Assist® software (Applied
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by the delta-Ct method normalized with our in-house
multiple reference genes.
Gene copy number
Patient and control genomic DNA was extracted using
the Allprep DNA/RNA Mini Kit (Qiagen) following the
manufacturer’s protocol. The concentration and purity
of the genomic DNA preparations were measured. Aur-
ora A gene amplification was analyzed with copy num-
ber assay by RT-qPCR on a PRIZM 7500 real-time PCR
System (Applied Biosystems, Foster city, CA). RNase P
was chosen as a reference for gene dosage because of its
single copy number. Each reaction was performed in
triplicate in a total volume of 20 μL, including 4 μL of
gDNA, 1 μL of AURKA TaqMan Copy Number Assay
(Hs02052288_cn, Applied Biosystems), 1 μL of RNase P
TaqMan Copy Number Reference Assay (4316844, Ap-
plied Biosystems), and 10 μL of Master Mix. Thermal
cycling conditions included an initialization step at 95°C
for 10 min, followed by 40-cycles of 15 s at 95°C and
60 s at 60°C. Calculation of the gene copy number was
carried out using the absolute quantification method.
Aurora A gene status was defined by the ratio of
AURKA versus RNase P gene. The cut-off level was
investigated with 40 cases of normal breast tissue
(Additional file 1: Figure S1), which defined a ratio of
1.70, the upper limit of 95% confidential interval, in-
dicating amplification.
Immunohistochemistry and scoring system
Histological sections (4 μm) were deparaffinized and
incubated for 10 min in methanol containing 0.3% hy-
drogen peroxide. We used rabbit polyclonal antibody
against Aurora A (Histofine MAX-PO, 1:100, Nichirei,
Japan), which targeted the N terminal of Aurora A kin-
ase. We also used mouse monoclonal antibodies against
ERα (SP1, Ventana Japan, Tokyo, Japan), progesterone
receptor (PgR) (1E2, Ventana Japan) and Ki67 (MIB1,
Dako Japan, Tokyo, Japan), and a polyclonal antibody
against Her2 (Dako Japan, 1:200); staining was carried
out in the NexES IHC Immunostainer (Ventana Medical
Systems, Tucson, AZ), in accordance with the manu-
facturer's instructions. Aurora A expression was scored
according to the respective different staining patterns,
predominantly cytoplasmic, however nuclear staining
was also seen. We evaluated each pattern of staining and
further combined scoring, which turned the cytoplasmic
staining out to be mostly correlated with clinical infor-
mation. Thus we scored the percentage of cytoplasmic
staining in the positively-stained tumor cells, as the
same way with Royce ME et al. [20]. Specimens in
which >50% of cells were stained were scored as strongly
positive (3+), those in which >20-50% of cells werestained were scored as moderately positive (2+), those in
which >5-20% of cells were stained were scored as
weakly positive (1+), and those in which <5% of cells
were stained, or where there was no staining, were
scored as negative (0). Ki67 was scored as the percentage
of nuclear-stained cells out of all cancer cells along the
invasive front of the tumor in ×400 high-power fields;
this gave the Ki67 labeling index. ER and PgR status
were evaluated based on the percentage of positively-
stained nuclei and the status of each was considered
positive when there was ≥1% of nuclear staining [21].
Her2 was evaluated using the HercepTest method
(Dako), with membranous staining scored on a scale of
0 to 3+. Tumors with scores of ≥3 or with a ≥2.2-fold in-
crease in HER2 gene amplification as determined by
fluorescence in situ hybridization were considered to be
positive for Her2 overexpression.
Statistical analysis
The nonparametric Wilcoxon (for uni-variable), Kruskal-
Wallis test (for multi-variables), and the χ2 test was adop-
ted for statistical analysis of the associations between
different Aurora A status and clinicopathological factors.
Relapse-free survival (RFS) and breast cancer-specific sur-
vival (BCSS) curves were calculated according to the
Kaplan-Meier method and verified by the log-rank test.
Univariate and multivariate analyses of prognostic values
were performed with the Cox’s proportional hazards
model. All statistical significance was defined as P < 0.05.
JMP software version 8.0.2 for Windows (SAS institute
Japan, Tokyo, Japan) was used for all statistical analyses.
Results
Correlation between Aurora A mRNA expression, gene
copy number and protein expression
We analyzed Aurora A mRNA expression, gene copy
number and protein expression in 278 primary invasive
breast tumors. Relative Aurora A mRNA expression
ranged from 0.0001 to 45.36 (median, 0.164). The me-
dian value for the ratio of Aurora A versus RNase P was
1.52. In total, 63 (23%) cases showed a ratio <1.0, 174
(63%) cases showed a ratio from 1.0 to 2.0, 37 (13%)
cases were from 2.0 to 4.0, and 4 (1%) cases were >4.0. If
a ratio >1.70 is defined as positive amplification, 78
(28%) cases were positive and 200 (72%) cases were
negative. Representative staining patterns for each Aur-
ora A protein expression level are shown in Figure 1.
Sixty-eight (24%) cases were weakly positive: 1+, moder-
ate: 2+, and strong: 3+ expression was present in 38
(14%), 13 (5%), and 17 (6%) cases, respectively, and 210
(75%) cases were negative: 0.
When we dichotomized Aurora A gene copy number
into positive and negative, Aurora A mRNA level was
higher in the patients exhibiting gene amplification;
Figure 1 Immunohistochemical staining patterns of Aurora A: a negative staining (no staining, <5%); b weakly positive
(≤5%, <20%); c moderately positive (≥20%, <50%); d strongly positive (≥50%). (Magnification ×400).
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dian mRNA; 0.209) and negative expression (n=200; me-
dian mRNA; 0.157) both in the entire cohort (P = 0.017;
Additional file 1: Figure S2a) and in the ER+/HER2- sub-
type group (P = 0.0035; Additional file 1: Figure S2b),
but not in the ER+ or- /HER2+ subtype group or the
ER-/HER2- (triple-negative) subtype group. Furthermore,
dividing into four subgroups according to the protein ex-
pression levels (negative, weakly positive, moderately po-
sitive and strongly positive groups); Aurora A mRNA
median levels were 0.157, 0.228, 0.067 and 0.578, respect-
ively (Additional file 1: Figure S3). There was mild correl-
ation between Aurora A mRNA and protein expression in
the entire cohort (P = 0.075), but no correlation within
each subtype. Additionally, no significant correlation was
indicated between Aurora A amplification and protein ex-
pression in the entire cohort (P = 0.553; Additional file 2:
Table S1).
Association of Aurora A mRNA expression, gene copy
number and protein expression with clinicopathological
characteristics
We examined the relationship between Aurora A mRNA
expression, gene copy number and protein expression,
and clinicopathological characteristics (Table 1). The
level of Aurora A mRNA expression was significantly
associated with several clinicopathological parameters.
Higher Aurora A mRNA levels were seen in the groupof patients with higher nuclear grade (P = 0.0004), nega-
tive PgR status (P = 0.016), as well as higher Ki67 label-
ing index (P < 0.0001). No significant relationship could
be found between the subtype groups, but the triple
negative group showed the highest Aurora A mRNA ex-
pression levels among all subtypes.
The Aurora A gene copy number had a less remar-
kable relationship with clinicopathological factors. Posi-
tive amplification was associated with larger tumor size
(P = 0.035), intermediate nuclear grade (P = 0.0044), and
higher Ki67 labeling index (P = 0.013). Aurora A protein
expression was associated with several clinicopathologi-
cal parameters, as well as Aurora A mRNA, such as
positive nodal status (P = 0.0083), higher nuclear grade
(P < 0.0001), negative ER status (P = 0.0084), and higher
Ki67 labeling index (P = 0.0015).
In the ER+/HER2- subtype group (n = 205), higher
Aurora A mRNA expression was associated with higher
nuclear grade (P = 0.0078) and higher Ki67 labeling in-
dex (P = 0.0005). Positive amplification was associated
with higher tumor size (P = 0.0051), nuclear grade 2 (P =
0.0080) and higher Ki67 labeling index (P = 0.0030). Aur-
ora A protein expression was associated with positive
nodal status (P = 0.018), higher nuclear grade (P = 0.0020)
and higher Ki67 labeling index (P =0.0030; Additional
file 2: Table S2). However, in the ER+ or- /HER2+ subtype
group (n = 42) and the ER-/HER2- (triple-negative) sub-
type group (n = 31), neither Aurora A mRNA level, gene
Table 1 Association of Aurora A mRNA expression, gene copy number and protein expression with clinicopathological
parameters
Clinical parameters No. of
patients
Aurora A mRNA expression Aurora A amplification Aurora A protein expression
Median (25%, 75%) P Negative (%) Positive (%) P Negative (%) Positive (%) P
Age(years)
<50 65 0.20 (0.08, 0.46) 0.67* 42 (65) 23 (35) 0.14‡ 47 (72) 18 (28) 0.49‡
≥50 213 0.16 (0.07, 0.43) 158 (74) 55 (26) 163 (77) 50 (23)
Menopause
Pre- 73 0.18 (0.07, 0.42) 0.89* 50 (68) 23 (32) 0.45‡ 54 (74) 19 (26) 0.72‡
Post- 205 0.16 (0.08, 0.45) 150 (73) 55 (27) 156 (76) 49 (24)
Tumor size (mm)
≤20 124 0.16 (0.08 , 0.36) 0.25* 97 (78) 27 (22) 0.035‡ 99 (80) 25 (20) 0.13‡
>20 154 0.18 (0.08, 0.52) 103 (67) 51 (33) 111 (72) 43 (28)
Nodal status
- 165 0.16 (0.06, 0.38) 0.14* 125 (76) 40 (24) 0.089‡ 134 (81) 31 (19) 0.0083‡
+ 113 0.17 (0.09, 0.52) 75 (66) 38 (34) 76 (67) 37 (33)
Nuclear grade
1 143 0.14 (0.06, 0.27) 0.0004† 114 (80) 29 (20) 0.0044‡ 123 (86) 20 (14) <0.0001‡
2 66 0.22 (0.10, 0.57) 38 (58) 28 (42) 45 (68) 21 (32)
3 68 0.31 (0.10, 0.76) 48 (71) 20 (29) 41 (60) 27 (40)
ER
- 61 0.20 (0.09, 0.66) 0.14* 43 (70) 18 (30) 0.78‡ 38 (62) 23 (38) 0.0084‡
+ 217 0.16 (0.08, 0.40) 157 (72) 60 (28) 172 (79) 45 (21)
PgR
- 94 0.23 (0.10, 0.56) 0.016* 71 (76) 23 (24) 0.34‡ 67 (71) 27 (29) 0.24‡
+ 184 0.14 (0.06, 0.38) 129 (70) 55 (30) 143 (78) 41 (22)
HER2
- 236 0.16(0.08, 0.42) 0.86* 169 (72) 67 (28) 0.77‡ 183 (76) 53 (22) 0.075‡
+ 42 0.15(0.08, 0.48) 31 (74) 11 (26) 27 (64) 15 (36)
Ki67
≦15% 91 0.11(0.06, 0.20) <0.0001* 74 (81) 17 (18) 0.013‡ 79 (87) 12 (13) 0.0015‡
> 15% 187 0.25(0.10, 0.58) 126 (67) 61 (32) 131 (70) 56 (30)
Tumor Subtype
ER+/HER2- 205 0.16(0.07, 0.39) 0.084† 150 (73) 55 (27) 0.39‡ 162 (79) 43 (21) 0.082‡
ER+ or –/HER2+ 42 0.15(0.08, 0.48) 31 (74) 11 (26) 27 (64) 15 (36)
ER-/HER2- (Triple Negative) 31 0.29(0.10, 0.79) 19 (61) 12 (39) 21 (68) 10 (32)
Statistical methods; *:Wilcoxon test, †:Kruskal-Wallis test, ‡χ2-test.
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cant association with clinicopathological parameters ex-
cept that Aurora A mRNA expression was higher with
higher Ki67 labeling index in the triple negative group
(P = 0.0026; Additional file 2: Tables S3-4).
Prognostic relevance of Aurora A mRNA expression, gene
copy number and protein expression
In the analysis of RFS, both local recurrences and distant
metastases were considered as events. Among 31 recur-
rent cases, there were 25 cases of distant metastases and
6 of local recurrences. Twenty patients died as a resultof breast cancer, and these were regarded as events
when analyzing BCSS. The prognostic relevance of Aur-
ora A mRNA, gene copy number and protein expression
are summarized in Tables 2 and 3. Our data indicate that
Aurora A mRNA expression is an independent predict-
ive factor of a poor prognosis in RFS for primary inva-
sive breast cancer, and is especially superior to Ki67. In
the Cox’s proportional hazards model, which included
age, menopausal status, tumor size, nodal status, nuclear
grade, ER, PgR, HER2 and Ki67, Aurora A mRNA expres-
sion proved to be a significant prognostic univariate par-
ameter (P = 0.006) and multivariate factor (P = 0.027) for
Table 2 Univariate and multivariate analysis for relapse-free survival (Cox’s proportional hazards model)
Variable Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
Age 1.03 0.46–2.59 0.95
Menopausal status 0.89 0.42–2.04 0.77
Tumor size 2.97 1.35–7.46 0.006 2.51 1.05–6.95 0.037
Nodal status 2.07 1.02–4.31 0.044 1.81 0.86–3.96 0.12
Nuclear grade 1.94 1.28–3.01 0.002 1.1 0.63–1.93 0.74
ER 0.21 0.11–0.44 <0.0001 0.29 0.12–0.72 0.0078
PgR 0.32 0.15–0.65 0.0017
Her2 1.26 0.47–2.87 0.63
Ki67 Labeling Index 2.3 0.96–6.82 0.063
Aurora A mRNA expression 2.54 1.25–5.25 0.010 2.3 1.10–4.92 0.027
Aurora A amplification 1.32 0.60–2.75 0.47
Aurora A protein expression 1.45 0.65–3.01 0.35
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was not a significant univariate parameter (P = 0.14;
Table 3).
To identify a clinically meaningful cut-off for Aurora
A mRNA expression, various levels of Aurora A mRNA
expression were tested by the Kaplan-Meier method and
verified by the log-rank test. An Aurora A mRNA ex-
pression level of 0.30 was identified as providing the
most significant association with RFS. In this setting, pa-
tients with high expression levels (n = 90, median 0.684)
had significantly poorer RFS than those with low expres-
sion levels (n = 188, median 0.101) (P = 0.0074;
Figure 2a).
Furthermore, we studied the prognostic value of
Aurora A in different subtypes of our cohort. In the ER
+/HER2- subtype group (n = 205), Aurora A gene ex-




Menopausal status 1.2 0.46–3.71
Tumor size 4.64 1.56–19.90
Nodal status 2.64 1.08–7.02




Ki67 Labeling Index 3.74 1.07–23.59
Aurora A mRNA expression 1.94 0.79–4.76
Aurora A amplification 0.86 0.28–2.24
Aurora A protein expression 1.38 0.49–3.47not significantly associated with either RFS nor BCSS
using the Cox’s proportional hazards model (Additional
file 2: Table S5) and could not be verified by the Kaplan-
Meier curve (Additional file 2: Table S4). Neither the
ER+ or- /HER2+ subtype group (n = 42) nor the ER-/
HER2- subtype group (n = 31) were not significantly as-
sociated with RFS and BCSS, as well as the ER+/HER2-
subtype group. When we defined the Aurora A gene
amplification and protein expression as either positive or
negative, in contrast to Aurora A mRNA expression,
there was no prognostic difference between the Aurora
A gene amplification and non-amplification groups, and
the Aurora A protein positive and negative groups.
Neither had significant correlation with RFS (Figures 3a
and 4a) or with BCSS (Figures 3b and 4b). Additionally,
in univariate analysis, there was no significant prog-
nostic value for either RFS (Aurora A gene amplification:r specific survival (Cox’s proportional hazards model)
Multivariate analysis
P HR 95% CI P
0.35
0.72
0.0042 3.56 0.92–23.44 0.068
0.033 2.35 0.90–6.92 0.083
0.0073 0.94 0.48–1.91 0.86
<0.0001 0.13 0.04–0.42 0.0005
<0.0001
0.84




Figure 2 Aurora A mRNA expression and survival. Kaplan-Meier
plots of the association of Aurora A mRNA expression with relapse-
free survival (RFS) (a) and breast cancer-specific survival (BCSS) (b) in
the entire cohort.
Figure 3 Aurora A amplification and survival. Kaplan-Meier plots
of the association of Aurora A amplification with relapse-free survival
(RFS) (a) and breast cancer-specific survival (BCSS) (b) in the
entire cohort.
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or BCSS (Aurora A gene amplification: P = 0.78, Aurora
A protein expression: P = 0.52; Table 3).
Discussion
Using a quantitative real time PCR-based assay, we
found that 28% of samples in our group showed Aurora
A gene amplification, a finding which was superior to
the result of Zhou’s research which showed amplification
in 12% of primary breast cancer cell lines [22]. Although
current studies suggested that copy number aberrations
could contribute to increases in DNA instability and lead
to genomic imbalance [23], and that copy number aber-
ration has a profound effect on inter-individual variation
in gene expression, Aurora A gene amplification did not
have any prognostic relevance in our study. We found a
significant correlation between the level of Aurora A
mRNA expression and gene amplification in the entire
cohort (P = 0.017; Additional file 1: Figure S2a) and
ER+ /HER2- subtype group (P = 0.0035; Additional file 1:
Figure S2b). It is reasonable that gene amplification shouldincrease the expression level of Aurora A mRNA [23,24],
although some cases exhibiting no amplification expressed
high Aurora A mRNA levels. In contrast, the association
between amplification and protein overexpression was
not absolutely significant in the entire cohort (P = 0.553;
Additional file 2: Table S1); 31% (n = 21) of protein
overexpression cases (n = 68) showed gene amplification.
Moreover, the correlation between mRNA and protein ex-
pression had no significance (P = 0.075; Additional file 1:
Figure S3). Discrepancies between gene amplification and
mRNA and protein over expression rates were previously
reported in small cohorts of several cancers [22]. All of
those suggested that Aurora A over expression was regu-
lated not only by gene amplification, but also by other
mechanisms such as transcriptional activation and sup-
pression of protein degradation. Kimura et al. reported
the rapid degradation of AIK1 (Aurora A) after mitotic
phase and the presence of destruction box-like sequences
in AIK1 (Aurora A), which suggested the involvement of
the ubiquitin-proteasome system in its degradation [25].
In normal cells, Aurora A protein levels are controlled at
Figure 4 Aurora A protein expression and survival. Kaplan-Meier
plots of the association of Aurora A protein expression with relapse-
free survival (RFS) (a) and breast cancer-specific survival (BCSS) (b) in
the entire cohort.
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[26]. We previously indicated that patients with lower
Fbxw7 mRNA expression had a poorer prognosis for
BCSS than those with higher expression [27]. In our co-
hort, for example, the positive Aurora A protein expres-
sion group showed lower Fbxw7 mRNA expression than
the Aurora A protein negative group (data not shown).
Recently, Chen BB et al. reported that Fbxl7, which is also
the SCF-based E3 ligase subunit, specifically ubiquitinates
and degrades Aurora A to regulate mitotic events in vitro
[28]. We speculate Fbxl7 has higher affinity for Aurora A
than Fbxw7 which predominantly work during G0 and
G1-S phase, and is also of great value for our next investi-
gation. Chen BB et al. also suggest that Aurora A is modu-
lated and regulated by a variety of post-translational
modifications, such as phosphorylation, dephosphoryla-
tion. The elucidation of these mechanisms and clarifying
their clinical significance hasten us for further studies.
We observed that Aurora A mRNA expression was
significantly higher in those patients who had active pro-
liferative parameters such as higher nuclear grade,negative hormone receptor and higher Ki67 labeling
index, as well as in the protein over expression group.
Additionally, Aurora A mRNA expression turned out to
be significantly associated with RFS (P = 0.0074) by di-
chotomous Kaplan-Meier curves, as well as the results
of univariate and multivariate RFS. Nowadays, gene ex-
pression profiling should be considered as an adjunct to
high-quality pathology phenotyping which results in an
indication of certain therapies for early breast cancer
patients [29] that contain Aurora A as one of the
proliferation-genes. Heibe-Kains et al. reported that
mRNA expression predicts classification into four mo-
lecular subtypes by quantitative measurement of three
genes on an array-based meta-analysis (ESR1, ERBB2
and AURKA) in a large study of breast cancer patients
(n = 5715), which identified the major breast cancer in-
trinsic subtypes and provided robust discrimination for
clinical use in a manner very similar to a 50-gene sub-
type predictor (PAM50) [30]. Our study provided power-
ful supporting data that coincide with these fundamental
investigations using Aurora A mRNA expression data.
Protein over expression of Aurora A in our study was
significantly associated with several clinicopathological
characteristics such as lymph node status, nuclear grade,
hormone receptor expression, and Ki67 labeling index,
which is in agreement with other studies demonstrating
that Aurora A over expression levels correlated with
higher nuclear grade in breast cancer [1,15,20,31]. Ali
et al. compared the prognostic value of proliferative
markers, such as MCM2, Ki67, Aurora A, polo-like kinase
1 (PLK1), GMNN and phosphorylated-histone H3
(PHH3), based on their differential expression in different
phases of the cell cycle, then showed that Aurora A is the
best prognostic factor, outperforming Ki67 in ER positive
breast cancer [15]. Our data also showed that Aurora A
protein over expression was associated with proliferation
parameters, but no longer had any prognostic significance
in the ER+ /HER2- subtype group. One explanation is that
Aurora A protein is expressed not only diffusely in the
cytoplasm but also as localized staining in the cytoplasm
or nucleus. In this study, we analyzed the proportion of
tumor cytoplasmic staining based on our previous study
[32] , which was still under development to provide uni-
versal guidelines as to whether nuclear and cytoplasmic
staining or cytoplasmic stainig was positive. Secondly, the
immunostaining technique was influenced by the antibody
used and the condition of the tissue block. Biopsy tissue,
for example, tended to stain strongly, which influenced the
studies, and Aurora A positive staining ranged from 15%
to 94%. In our tissue, 17 strongly positive cases (6%) were
found to contain diffuse staining in the cytoplasma all over
the tumor, but in other cases the staining was mainly lo-
calized in a part of the tumor. By establishing stan-
dardized guidelines for immunohistochemistry, Aurora
Yamamoto et al. BMC Cancer 2013, 13:217 Page 9 of 10
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for select cases which need more intensive cytotoxic
therapy.
Recently, several inhibitors of Aurora kinase such as
Hesperadin [33], ZM447439 [34], and VX680 [35] have
been developed, which have been designed to target the
ATP-binding site of Aurora kinases and thus inhibit all
three Aurora kinases. In vivo and in vitro studies show
that the inhibition of tumor growth was paralleled by
a significant increase in tumor cell apoptosis. Further-
more, VX680 had no effect on the viability of non-
cycling primary human cells, probably because the
expression and activity of Aurora A kinases is low or
undetectable in normal cells, thus molecular inhibi-
tors of Aurora A kinases could be promising antican-
cer therapeutics [36,37]. Further work is needed to
establish patterns of Aurora A expression and the res-
ponse to Aurora A inhibitors.
Conclusions
We analyzed Aurora A expression using three different
methods, gene expression, copy number variation using
RT-qPCR, and protein expression by immunohistochem-
istry. Aurora A protein expression was associated with
aggressive proliferative parameters, whereas Aurora A
mRNA expression was associated not only with poor
RFS but also turned out to be an independent biomarker
for RFS. Our results suggest that Aurora A expression is
an effective tool which can detect tumor proliferation
potency, and is considered to be an important part of
gene expression profiling for the biological diversity of
breast cancer. Further research including Aurora A sig-
naling is needed.Additional files
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